Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | VP301 |
Synonyms | |
Therapy Description |
VP301 is a bispecific antibody targeting CD38 and ICAM1, which potentially induces antibody-dependent cellular cytotoxicity and phagocytosis of tumor cells expressing CD38 and ICAM1 (PMID: 37816503). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VP301 | VP-301|VP 301 | CD38 Antibody 20 | VP301 is a bispecific antibody targeting CD38 and ICAM1, which potentially induces antibody-dependent cellular cytotoxicity and phagocytosis of tumor cells expressing CD38 and ICAM1 (PMID: 37816503). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05698888 | Phase I | VP301 | Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors | Terminated | USA | 0 |